Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Jean‐Claude Tardif(Tufts Medical Center), Guy Boivin(Université Laval), Pierre‐Olivier Hétu(Centre Hospitalier de l’Université de Montréal), David D. Waters(San Francisco General Hospital), Marie‐Claude Guertin, Andreas Orfanos, Elisabeth Goulet(Montreal Heart Institute), Denis Fortin(Montreal Heart Institute), Jean‐Sébastien Paquette(Université Laval), Jean‐Claude Grégoire(Montreal Heart Institute), Spyridon Deftereos(National and Kapodistrian University of Athens), Marie‐Pierre Dubé(Montreal Heart Institute), Christian Lavallée(Hôpital Maisonneuve-Rosemont), Philippe L. L’Allier(Montreal Heart Institute), Sarah Samson(Montreal Heart Institute), André Denault(Montreal Heart Institute), Norman E. Lepor(University of California, Los Angeles), Sylvie Lévesque, Martin Pelletier(Institut National de la Recherche Scientifique), Lambert Busque(Hôpital Maisonneuve-Rosemont), Priscilla Y. Hsue, Binita Shah(New York University), Malorie Chabot-Blanchet, Nicolas Sainturet, Nadia Bouabdallaoui(Montreal Heart Institute), Zohar Bassevitch, Lucie Verret(Montreal Heart Institute), Anick Dubois(Montreal Heart Institute), Protásio Lemos da Luz(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Frédéric Lesage(Montreal Heart Institute), Avni Y. Joshi(Mayo Clinic in Arizona), Jocelyn Dupuis(Montreal Heart Institute), Sylvia Audet(Montreal Heart Institute), David Busseuil(Montreal Heart Institute), Michael H. Pillinger(United States Department of Veterans Affairs), Philippe A. Tessier(Université Laval), Gabriela Stamatescu, José López‐Sendón(Hospital Universitario La Paz), Eve Roy-Clavel, Daniel Gaudet(Brigham and Women's Hospital), Jean-Daniel Tardif(Montreal Heart Institute), Chantal Lacoste(Montreal Heart Institute), Mariève Cossette, Anna Nozza
The Lancet Respiratory Medicine
May 27, 2021
Cited by 271


Related Papers